Investor Column Group Ii, Lp
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Column Group Ii, Lp . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2024-12-23 13D/A RAPT / RAPT Therapeutics, Inc. 4,425,439 1,603,593
2024-11-14 13G/A ORIC / ORIC Pharmaceuticals, Inc. 3,671,522 3,644,118
2023-11-22 13D/A EFTR / eFFECTOR Therapeutics, Inc. 4,091,734 0
2023-09-15 13D/A EFTR / eFFECTOR Therapeutics, Inc. 4,309,329 4,091,734
2023-01-13 13D/A RAPT / RAPT Therapeutics, Inc. 3,156,228 4,425,439
2022-02-11 13G/A ORIC / ORIC Pharmaceuticals, Inc. 4,768,181 3,671,522
2021-09-20 13D/A RAPT / RAPT Therapeutics, Inc. 4,357,247 3,156,228
2021-09-07 13D EFTR / eFFECTOR Therapeutics, Inc. 4,309,329
2021-08-30 13D/A RAPT / RAPT Therapeutics, Inc. 5,652,997 4,357,247
2021-02-16 13G/A GRTS / Gritstone bio, Inc. 0 0
2021-02-16 13G ORIC / ORIC Pharmaceuticals, Inc. 4,768,181 4,768,181
2021-02-16 13G/A GRTS / Gritstone bio, Inc. 3,102,934 0
2021-02-16 13G ORIC / ORIC Pharmaceuticals, Inc. 4,768,181 4,768,181
2020-11-04 13G/A RCUS / Arcus Biosciences, Inc. 3,540,850 0
2020-10-01 13D/A RAPT / RAPT Therapeutics, Inc. 6,260,997 5,652,997
2020-08-26 13D/A RAPT / RAPT Therapeutics, Inc. 6,777,151 6,260,997
2020-02-14 13D/A RAPT / RAPT Therapeutics, Inc. 6,777,151 6,777,151
2019-11-08 13D RAPT / RAPT Therapeutics, Inc. 6,777,151
2019-02-13 13G RCUS / Arcus Biosciences, Inc. 3,540,850
2019-02-13 13G GRTS / Gritstone bio, Inc. 3,102,934